GCM
PRVB

Graham Capital Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Graham Capital Management’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-80,163
Closed -$360K – 1439
2022
Q3 		$360K Buy
+80,163
New +$365K 0.01% 840
2022
Q2 		– Sell
-37,060
Closed -$271K – 1311
2022
Q1 		$271K Buy
37,060
+16,483
+80% +$98.6K 0.01% 760
2021
Q4 		$115K Buy
+20,577
New +$131K ﹤0.01% 501

Other funds holding PRVB

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Graham Capital Management's PRVB Position: Q4 2022 in Review

Graham Capital Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q4 2022, closing a stake of 80,163 shares — an estimated $360K sold.

Graham Capital Management first reported a position in PRVB in Q4 2021 and held it in 3 quarters. The position peaked at $360K in Q3 2022. 133 funds tracked by Wall St. Rank hold PRVB as of Q4 2022.

  • Graham Capital Management reported no remaining Provention Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Graham Capital Management sold 80,163 Provention Bio, Inc. Common Stock shares in Q4 2022, an estimated $360K.
  • Graham Capital Management first reported a position in Provention Bio, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • Graham Capital Management's Provention Bio, Inc. Common Stock position peaked at $360K in Q3 2022.
  • 133 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q4 2022.

Based on Graham Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.